723 A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti–PD1 and anti–LAG-3 antibody, in patients with select advanced malignancies
Regular and Young Investigator Award Abstracts（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要